World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
75661
World Ranking
2551
National Ranking
1435

Overview

Kris V. Kowdley is affiliated with Washington State University in the United States. Their research primarily spans the field of Medicine, with a strong focus on Hepatology, Epidemiology, Surgery, Pulmonary and Respiratory Medicine, and Endocrinology, Diabetes, and Metabolism.

The scientist's work centers on several main topics within liver-related health, including:

  • Liver Disease Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Pediatric Hepatobiliary Diseases and Treatments
  • Gallbladder and Bile Duct Disorders
  • Liver Disease and Transplantation
  • Diet, Metabolism, and Disease
  • Hepatitis C virus research

Kowdley has contributed to numerous publications, with notable papers including:

  • "A multisociety Delphi consensus statement on new fatty liver disease nomenclature," 2023, Hepatology
  • "A multisociety Delphi consensus statement on new fatty liver disease nomenclature," 2023, Journal of Hepatology
  • "Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease," 2021, New England Journal of Medicine
  • "A multisociety Delphi consensus statement on new fatty liver disease nomenclature," 2023, Annals of Hepatology
  • "Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH," 2023, New England Journal of Medicine

The principal venues where Kowdley has published extensively include:

  • Journal of Hepatology
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Hepatology
  • Hepatology Communications

Among frequent collaborators, Kowdley has coauthored with:

  • Rohit Loomba
  • Cynthia Levy
  • Christopher L. Bowlus
  • Gideon M. Hirschfield
  • Marlyn J. Mayo

Best Publications

  • Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

    Arun J. Sanyal;Naga Chalasani;Kris V. Kowdley;Arthur McCullough

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

    Brent A Neuschwander-Tetri;Rohit Loomba;Arun J Sanyal;Joel E Lavine

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

    Fred Poordad;Christophe Hezode;Roger Trinh;Kris V. Kowdley

  • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    Jordan J. Feld;Kris V. Kowdley;Eoin Coakley;Samuel Sigal

  • A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser

  • Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

    Keith D. Lindor;Kris V. Kowdley;E. Jenny Heathcote;M. Edwyn Harrison

  • Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

    Marion G. Peters;H. W. Hann;Paul Martin;E. Jenny Heathcote

  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

    Michael Charlton;Gregory T. Everson;Steven L. Flamm;Princy Kumar

  • All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

    David R. Nelson;James N. Cooper;Jacob P. Lalezari;Eric Lawitz

  • Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.

    Bruce R. Bacon;Paul C. Adams;Kris V. Kowdley;Lawrie W. Powell

  • Global epidemiology of hepatitis B virus.

    Brian Custer;Sean D. Sullivan;Thomas K. Hazlet;Uchenna Iloeje

  • High Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis

    Keith D. Lindor;Kris V. Kowdley;Velimir A.C. Luketic;M. Edwyn Harrison

  • Endpoints and clinical trial design for nonalcoholic steatohepatitis.

    Arun J. Sanyal;Elizabeth M. Brunt;David E. Kleiner;Kris V. Kowdley

  • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

    Marc Bourlière;Stuart C. Gordon;Steven L. Flamm;Curtis L. Cooper

  • Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.

    Arun J. Sanyal;Mark L. van Natta;Jeanne Clark;Brent A. Neuschwander-Tetri

  • A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis

    Scott L. Friedman;Vlad Ratziu;Stephen A. Harrison;Manal F. Abdelmalek

  • Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

    Gideon M. Hirschfield;Andrew Mason;Velimir Luketic;Velimir Luketic;Keith Lindor;Keith Lindor

Frequent Co-Authors

Keith D. Lindor
Keith D. Lindor Arizona State University
Gideon M. Hirschfield
Gideon M. Hirschfield University Health Network
Albert Parés
Albert Parés University of Barcelona
Naga Chalasani
Naga Chalasani Indiana University
Bettina E. Hansen
Bettina E. Hansen University Health Network
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Rohit Loomba
Rohit Loomba University of California, San Diego
Zobair M. Younossi
Zobair M. Younossi Inova Health System
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University
Harry L.A. Janssen
Harry L.A. Janssen Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean following the traditional MD route—many rewarding paths now start online. For those interested in entering nursing quickly, you may want to consider nursing schools that don't require teas test. These programs remove the barrier of certain standardized exams, making admission more accessible.

If you’d rather focus on the administrative side of healthcare, an online healthcare administration associate degree online can open doors to roles in management, operations, or medical records.

Registered nurses looking to advance their careers can take advantage of specialized programs like the adn to fnp bridge, helping transition from an associate degree in nursing to a nurse practitioner role for greater responsibility and earning potential.

Those interested in preventative medicine and public health might prefer nutrition-related fields. The best online nutrition degree programs prepare students to become dietitians, nutritionists, or wellness educators.

Each of these flexible online pathways offers unique ways to build a fulfilling healthcare career beyond medical school.

Best Scientists Citing Kris V. Kowdley

Trending Scientists

Recently Published Articles